Evidence map›Paper›PMID 38699073›Full record

ArticleJHEP reports : innovation in hepatology2024

Predictive role of hepatic venous pressure gradient in bleeding events among patients with cirrhosis undergoing orthotopic liver transplantation.

Mikhael Giabicani, Pauline Joly, Stéphanie Sigaut, Clara Timsit, Pauline Devauchelle, Fédérica Dondero, François Durand, Pierre Antoine Froissant, Myriam Lamamri, Audrey Payancé and 7 more

Registry-linked trialAbstract read
In one paragraph

Article in JHEP reports : innovation in hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07304466 (Comparison of the Effects of Terlipressin and Somatostatin on Portal Pressure in Patients Undergoing Living Donor Liver Transplantation), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07304466 narecruitingstarted 2025, after this paper: background citation

Comparison of the Effects of Terlipressin and Somatostatin on Portal Pressure in Patients Undergoing Living Donor Liver Transplantation

Ran2025Enrolled50Registered outcomes8Posted comparisons0ConditionsLiver Transplantation, Portal HypertensionArmssomatostatin, Terlipressin
Open the trial in the graph
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Diagnosis of Portal Hypertension.Diagnostics (Basel, Switzerland) · 2025
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Mikhael GiabicaniDépartement d'anesthésie réanimation, AP-HP, Hôpital Beaujon, DMU PARABOL, Clichy, France.
Pauline JolyDépartement d'anesthésie réanimation, AP-HP, Hôpital Beaujon, DMU PARABOL, Clichy, France.
Stéphanie SigautDépartement d'anesthésie réanimation, AP-HP, Hôpital Beaujon, DMU PARABOL, Clichy, France.
Clara TimsitDépartement d'anesthésie réanimation, AP-HP, Hôpital Beaujon, DMU PARABOL, Clichy, France.
Pauline DevauchelleDépartement d'anesthésie réanimation, AP-HP, Hôpital Beaujon, DMU PARABOL, Clichy, France.
Fédérica DonderoDepartement of HPB Surgery & Liver Transplantation, AP-HP, Beaujon Hospital, DMU DIGEST, Université Paris-Cité, Clichy, France.
François DurandService d'Hépatologie, AP-HP, Hôpital Beaujon, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Clichy, France.
Pierre Antoine FroissantDépartement d'anesthésie réanimation, AP-HP, Hôpital Beaujon, DMU PARABOL, Clichy, France.
Myriam LamamriDépartement d'anesthésie réanimation, AP-HP, Hôpital Beaujon, DMU PARABOL, Clichy, France.
Audrey PayancéService d'Hépatologie, AP-HP, Hôpital Beaujon, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Clichy, France.
Aymeric RestouxDépartement d'anesthésie réanimation, AP-HP, Hôpital Beaujon, DMU PARABOL, Clichy, France.
Olivier RouxService d'Hépatologie, AP-HP, Hôpital Beaujon, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Clichy, France.
Tristan Thibault-SogorbDépartement d'anesthésie réanimation, AP-HP, Hôpital Beaujon, DMU PARABOL, Clichy, France.
Shantha Ram ValainathanService d'Hépatologie, AP-HP, Hôpital Beaujon, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Clichy, France.
Mickaël LesurtelUniversité Paris-Cité, Inserm, Centre de recherche sur l'inflammation, UMR 1149, Paris, France.
Pierre-Emmanuel RautouService d'Hépatologie, AP-HP, Hôpital Beaujon, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Clichy, France.
Emmanuel WeissDépartement d'anesthésie réanimation, AP-HP, Hôpital Beaujon, DMU PARABOL, Clichy, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: Major bleeding events during orthotopic liver transplantation (OLT) are associated with poor outcomes. The proportion of this risk related to portal hypertension is unclear. Hepatic venous pressure gradient (HVPG) is the gold standard for estimating portal hypertension. The aim of this study was to analyze the ability of HVPG to predict intraoperative major bleeding events during OLT in patients with cirrhosis. Methods: We retrospectively analyzed a prospective database including all patients with cirrhosis who underwent OLT between 2010 and 2020 and had liver and right heart catheterizations as part of their pre-transplant assessment. The primary endpoint was the occurrence of an intraoperative major bleeding event. Results: The 468 included patients had a median HVPG of 17 mmHg [interquartile range, 13-22] and a median MELD on the day of OLT of 16 [11-24]. Intraoperative red blood cell transfusion was required in 72% of the patients (median 2 units transfused), with a median blood loss of 1,000 ml [575-1,500]. Major intraoperative bleeding occurred in 156 patients (33%) and was associated with HVPG, preoperative hemoglobin level, severity of cirrhosis at the time of OLT (MELD score, ascites, encephalopathy), hemostasis impairment (thrombocytopenia, lower fibrinogen levels), and complications of cirrhosis (sepsis, acute-on-chronic liver failure). By multivariable regression analysis with backward elimination, HVPG, preoperative hemoglobin level, MELD score, and tranexamic acid infusion were associated with the primary endpoint. Three categories of patients were identified according to HVPG: low-risk (HVPG <16 mmHg), high-risk (HVGP ≥16 mmHg), and very high-risk (HVPG ≥20 mmHg). Conclusions: HVPG predicted major bleeding events in patients with cirrhosis undergoing OLT. Including HVPG as part of pre-transplant assessment might enable better anticipation of the intraoperative course. Impact and implications: Major bleeding events during orthotopic liver transplantation (OLT) are associated with poor outcomes but the proportion of this risk related to portal hypertension is unclear. Our work shows that hepatic venous pressure gradient (HVPG), the gold standard for estimating portal hypertension, is a strong predictor of major bleeding events and blood loss volume in patients with cirrhosis undergoing OLT. Three groups of patients can be identified according to their risk of major bleeding events: low-risk patients with HVPG <16 mmHg, high-risk patients with HVPG ≥16 mmHg, and very high-risk patients with HVPG ≥20 mmHg. HVPG could be systematically included in the pre-transplant assessment to anticipate intraoperative course and tailor patient management.

Indexed as

bleedingcirrhosishepatic venous pressure gradientliver transplantationportal hypertensionpre-transplant assessment

Identifiers

PMID38699073
PMCPMC11060951

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.